Materia Ventures partners with Feather to bring Hiatus, the premium CBD vape brand, to the UK

London, April 14, 2020 - Materia Ventures («Materia» or the »Company«), a medical cannabis and wellness company focused on the European market, today announced an exclusive licensing and distribution agreement with Feather Company Ltd. (»Feather") to bring its premium Hiatus CBD brand to the UK.

«We're delighted to bring Hiatus to the UK as we expand our portfolio of some of the industry's most respected brands,» said Deepak Anand, CEO of Materia. «Vape pens are the second largest CBD product segment in the UK and consumers trust companies that don't compromise on safety and quality. We believe that Hiatus, Feather's CBD brand, embodies these principles, making it an ideal addition to our portfolio.»

Nick Pateras, Managing Director, Europe at Materia, added: «Over a quarter of UK CBD consumers claim to use vapes, which represented a segment worth £80 million last year and is growing rapidly. Given the serious health issues reported by some off-label products, consumers need to be vigilant in the products they choose. Hiatus applies best-in-class practices to produce its innovative material, and Materia's formulations meet the highest quality standards for manufacturing and testing, making health and well-being the top priority.»

Hiatus is a premium brand designed to appeal specifically to discerning consumers. The spray pen is built with the highest quality materials and offers an iconic yet understated consumer experience.

Hiatus will be offered in three varieties, targeting the highest states of need for rest, focus and boost. The launch will focus on established online distribution channels, then expand to physical stores as permitted by the UK retail environment.

Under the terms of the agreement, Materia will manufacture and obtain exclusive rights to market and distribute Hiatus's CBD disposable pen and cartridge technology.

«At Feather, we believe that good design has universal appeal, and the opportunity to bring our intuitive product experiences to a wider audience is what drives us,» said Feather CEO Patrick Lehoux.

«Materia shares our passion for quality and customer experience and brings extensive expertise in navigating the competitive and regulatory environment in the UK. We are delighted to partner with them to launch Hiatus and bring a quality CBD consumption experience to all Brits.»

About Materia Ventures

Materia Ventures' vision is to facilitate access to cannabis worldwide. Materia is developing a strong manufacturing and distribution ecosystem to expand the legal cannabis market on the European continent. With its expertise, research team and cutting-edge technology, Materia focuses on the high-margin downstream activities of processing, formulation and distribution to markets wherever a patient needs cannabis-based medicine.

About Feather Company

Feather Company Ltd. is a lifestyle design brand. We believe that good design combined with quality cannabis makes for great intuitive experiences. Our mission is simple, we make great products that enhance everyday life, one person and one moment at a time. With offices in Toronto, Sudbury and Ottawa, our multidisciplinary teams include branding, product design, R&D and marketing.

Hiatus is a premium CBD brand with a mission to deliver quality experiences to sophisticated, educated consumers.

For further information, please contact :

Dennis Fong, Investor Relations
Telephone: 1-416-283-9930
E-mail: [email protected]
Website: http://www.materiaventures.com/

Patrick Lehoux, CEO, Feather
Email: [email protected]

WARNING

All statements other than statements of historical fact in this press release are forward-looking statements that are based on expectations, estimates and projections as of the date of this press release. Any statement that involves discussions regarding future forecasts, expectations, beliefs, plans, projections, objectives, assumptions, events or performance is not a statement of historical fact and may constitute a forward-looking statement. In this press release, forward-looking statements relate to, among other things, the timetable for receiving the completion of the Malta facility and obtaining EU-GMP certification, as well as the expected size of the European medical cannabis market. Forward-looking statements are necessarily based on a number of estimates and assumptions which, although considered reasonable, are subject to known and unknown risks, uncertainties and other factors that may cause actual results and future events to differ materially from those expressed or implied by forward-looking statements. These factors include, but are not limited to: general business, economic, competitive, political and legal uncertainties, access to financing, delay or failure to receive regulatory approvals, and other factors. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Materia Ventures assumes no obligation to update statements of belief, opinions, projections or other forward-looking factors, if any.